Optimal Medical Therapy for Stable Ischemic Heart Disease in 2024: Focus on Blood Pressure and Lipids.

Hypertension and dyslipidemia are 2 highly prevalent and modifiable risk factors in patients with stable ischemic heart disease. Multiple lines of evidence demonstrate that lowering blood pressure and low-density lipoprotein cholesterol improves clinical outcomes in patients with ischemic heart disease. Accordingly, clinical guidelines recommend intensive treatment targets for these high-risk patients. This article summarizes the pathophysiology, supporting evidence, and treatment recommendations for management of hypertension and dyslipidemia among patients with manifest ischemic heart disease and points to future research and unmet clinical needs.

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Disclosure T. Abrahams has no disclosures. S.J. Nicholls has received research support from AstraZeneca, United Kingdom, Amgen, United States, Anthera, CSL Behring, United States, Cerenis, Eli Lilly, Esperion, United States, Resverlogix, Novartis, Switzerland, InfraRedx, United States, and Sanofi-Regeneron; and is a consultant for Amgen, Akcea, AstraZeneca, Boehringer Ingelheim, CSL Behring, Eli Lilly, Esperion, Kowa, Merck, Takeda, Pfizer, Sanofi-Regeneron, Novo Nordisk, CSL Sequiris, and Vaxxinity. A.J. Nelson has received research support from Amgen, Eli Lilly, Novartis and Boehringer Ingelheim; and is a consultant for Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck, Sanofi, Novo Nordisk, CSL Sequiris, and Vaxxinity.